SCHEMBL4244853

SCHEMBL4244853

NNC(=O)c1ccc(NC(=O)c2ccccc2)cc1C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
MAPT P10636 3/20 0.65
MEN1 O00255 2/20 0.65
LMNA P02545 1/20 0.65
KCNK3 O14649 4/20 0.64
KCNK9 Q9NPC2 3/20 0.64
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
P2RX1 P51575 1/20 0.54
PKM P14618 1/20 0.52
NPSR1 Q6W5P4 2/20 0.51
XBP1 P17861 1/20 0.51
EPHX1 P07099 1/20 0.51
MPO P05164 1/20 0.51
PTGS1 P23219 1/20 0.50
AVPR2 P30518 1/20 0.50
GPR27 Q9NS67 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245072 0.84 MEN1 (0.57) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL7745875 0.83 MAPT (0.76) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL4238475 0.83 MAPT (0.64) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL3531261 0.82 MAPT (0.70) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL4241801 0.82 NPC1 (0.68) KMT2AMAPTMEN1KCNK3KCNK9
SCHEMBL6250922 0.80 MAPT (0.72) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL850791 0.79 MEN1 (1.00) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL6055167 0.79 LMNA (0.70) KMT2AMAPTMEN1LMNAKCNK3
SCHEMBL4247707 0.79 NPC1 (0.68) KMT2AMAPTKCNK3KCNK9NPC1
SCHEMBL7553405 0.77 KMT2A (0.61) KMT2AMAPTMEN1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009071519-A9 OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2009-12-03 WO disclosed
WO-2009071519-A1 OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2009-06-11 WO disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 KMT2A 2842/4885MAPT 659/4885MEN1 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.